Last updated 2 days ago

Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Plus Chemotherapy in Participants With Metastatic Esophageal Carcinoma (MK-7902-014/E7080-G000-320/LEAP-014)

862 patients around the world

Available in Argentina, Chile, Spain

There will be 2 parts to the study: the cisplatin and 5-fluorouracil (5-FU) (FP) and paclitaxel and cisplatin (TP) Safety Run-in (Part 1) and the Main Study (Part 2). In Part 1 (FP and TP Safety Run-in), participants will be treated with pembrolizumab plus lenvatinib plus FP or TP. Dose-limiting toxicities, safety, and tolerability will be assessed. In Part 2 (Main Study), participants (not including those participating in Part 1) will be treated with pembrolizumab plus lenvatinib plus chemotherapy or pembrolizumab plus chemotherapy. Efficacy, safety, and tolerability will be assessed.

Merck Sharp & Dohme Corp.

26Research sites

862Patients around the world

This study is for people with

Esophageal cancer

Requirements for the patient

From 18 Years

All Gender

Medical requirements

: Has a histologically or cytologically confirmed diagnosis of metastatic squamous cell carcinoma of the esophagus
Male participants are abstinent from heterosexual intercourse or agree to use contraception during the intervention period and for at least 7 days after the last dose of lenvatinib or 90 days after the last dose of chemotherapy, whichever comes last; 7 days after lenvatinib is stopped, if the participant is on pembrolizumab only and is greater than 90 days post chemotherapy, no male contraception is needed
Female participant is not pregnant or breastfeeding and is not a woman of childbearing potential (WOCBP) or is a WOCBP using a contraceptive method that is highly effective or is abstinent from heterosexual intercourse as their preferred and usual lifestyle during the intervention period and for at least 120 days after the last dose of pembrolizumab, 30 days after the last dose of lenvatinib, or 180 days after the last dose of chemotherapy, whichever occurs last, and agrees not to donate eggs during this period
Has adequately controlled blood pressure (BP) with or without antihypertensive medications, defined as BP≤150/90 millimeters of mercury (mm Hg) with no change in antihypertensive medications within 1 week prior to randomization
Has adequate organ function

: Has had previous therapy for locally advanced unresectable or metastatic esophageal cancer
Has locally advanced esophageal carcinoma
Has metastatic adenocarcinoma of the esophagus
Has direct invasion into adjacent organs such as the aorta or trachea
Has radiographic evidence of encasement of a major blood vessel, or of intratumoral cavitation
Has perforation risks or significant gastrointestinal (GI) bleeding
Has had clinically significant hemoptysis within 3 weeks prior to the first dose of study drug or tumor bleeding within 2 weeks prior to the first dose of study intervention
Has uncontrollable pleural effusion, pericardial effusion, or ascites requiring frequent drainage or medical intervention
Has GI obstruction, poor oral intake, difficulty in taking oral medication, or existing esophageal stent
Has had major surgery, open biopsy, or significant traumatic injury within 3 weeks prior to first dose of study interventions
Has received prior radiotherapy within 2 weeks of start of study intervention or have had a history of radiation pneumonitis
Has received a live or live attenuated vaccine within 30 days prior to the first dose of study intervention; administration of killed vaccines is allowed
Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy or any form of immunosuppressive therapy within 7 days prior to the first dose of study intervention, or has a history of organ transplant, including allogeneic stem cell transplant
Has a known additional malignancy that is progressing or has required active treatment within the past 3 years
Has known active central nervous system (CNS) metastases and/or carcinomatous meningitis
Has an active autoimmune disease that has required systemic treatment in past 2 years; replacement therapy is not considered a form of systemic treatment and is allowed
Has a history of non-infectious pneumonitis/interstitial lung disease that required steroids or current pneumonitis/interstitial lung disease
Has poorly controlled diarrhea
Has clinically significant cardiovascular disease within 12 months from first dose of study intervention
Has peripheral neuropathy ≥Grade 2
Has a known history of human immunodeficiency virus (HIV) infection
Has a known history of Hepatitis B or know active Hepatitis C virus infection
Has a weight loss of >20% within the last 3 months

Sites

Instituto San Marcos Investigación - San Juan

Recruiting

Sarmiento 92 norte, San Juan

Hospital Provincial del Centenario - Rosario, Santa Fe

Recruiting

Urquiza 3101, Rosario, Santa Fe

Fundación Cori para la Investigación y Prevención del Cáncer - La Rioja

Recruiting

Dorrego 269, La Rioja

Sociedad de Beneficencia Hospital Italiano - Córdoba

Recruiting

Roma 550, Bº General Paz, Córdoba

Instituto de Investigaciones Clínicas Mar del Plata

Recruiting

Av. Colón 3456, Mar del Plata, Buenos Aires

Instituto Médico de la Fundación Estudios Clínicos - Rosario

Recruiting

Italia 428, Rosario - Santa Fe

Sanatorio Parque - Rosario

Recruiting

Boulevard Oroño 860, Rosario, Santa Fe

Instituto de Neurociencias Fundación Favaloro

Recruiting

Solis 461, CABA, Buenos Aires

Centro de Oncología e Investigación Buenos Aires COIBA

Recruiting

Calle 12 Nro 4756, Berazategui, Buenos Aires

Centro de Investigación Clínica Bradford Hill - Santiago, Región Metropolitana

Recruiting

Manzano 343, Recoleta, Región Metropolitana, Santiago

StudyLEAP-014

SponsorMerck Sharp & Dohme Corp.

Study typeInterventional

Conditions

Esophageal cancer

Requirements

From 18 YearsAll Gender

Unique study IDclinicaltrials.gov

NCT04949256